Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Kim Sheva"'
Autor:
Walid Shalata, Ashraf Abu Jama, Yulia Dudnik, Omar Abu Saleh, Sondos Shalata, Lena Tourkey, Kim Sheva, Amichay Meirovitz, Alexander Yakobson
Publikováno v:
Medicina, Vol 60, Iss 8, p 1270 (2024)
Recent advancements in targeted therapies for non-small-cell lung cancer (NSCLC), specifically focusing on epidermal growth factor receptor (EGFR) mutations, have revolutionized treatment strategies. Osimertinib, an approved therapy for metastatic NS
Externí odkaz:
https://doaj.org/article/833e69e8065c4b8294cd11b9b3ba10b5
Autor:
Heba Alkhatib, Ariel M. Rubinstein, Swetha Vasudevan, Efrat Flashner-Abramson, Shira Stefansky, Sangita Roy Chowdhury, Solomon Oguche, Tamar Peretz-Yablonsky, Avital Granit, Zvi Granot, Ittai Ben-Porath, Kim Sheva, Jon Feldman, Noa E. Cohen, Amichay Meirovitz, Nataly Kravchenko-Balasha
Publikováno v:
Genome Medicine, Vol 14, Iss 1, Pp 1-17 (2022)
Abstract Background Drug resistance continues to be a major limiting factor across diverse anti-cancer therapies. Contributing to the complexity of this challenge is cancer plasticity, in which one cancer subtype switches to another in response to tr
Externí odkaz:
https://doaj.org/article/1bfb8d0fe62b40729734ee0a48f29698
Autor:
Walid Shalata, Rachel Steckbeck, Ilya Polishchuk, Ahron Yehonatan Cohen, Keren Rouvinov, Margarita Tokar, Ashraf Abu Jama, Omar Abu Saleh, Kim Sheva, Alexander Yakobson
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
This case report describes the occurrence of hyperbilirubinemia as a complication of metastatic melanoma. A 72-year-old male patient was diagnosed with BRAF V600E-mutated melanoma with metastases in the liver, lymph nodes, lungs, pancreas, and stomac
Externí odkaz:
https://doaj.org/article/cffe25d51cba484f9b2a30327de7f0da
Autor:
Amichay Meirovitz, Shani Bergerson, Nir Hirshoren, Jeffrey M. Weinberger, Evgeniya Bersudski, Sharon Daniel, Kim Sheva, Cesar A. Perez
Publikováno v:
Cancer Reports, Vol 5, Iss 3, Pp n/a-n/a (2022)
Abstract Background The standard chemotherapy treatment protocol for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) requires as long as 56 days of hospitalization over six months. Where the 5‐Fluorouracil (5‐FU)
Externí odkaz:
https://doaj.org/article/9a97ccfa91ea4bb9927b27a3211c185b
Autor:
Alexia Abecassis, Esther Hermano, Kim Sheva, Ariel M. Rubinstein, Michael Elkin, Amichay Meirovitz
Publikováno v:
Biomedicines, Vol 11, Iss 3, p 710 (2023)
Agents used to reduce adverse effects common in cancer treatment modalities do not typically possess tumor-suppressing properties. We report that heparanase, an extracellular matrix-degrading enzyme, is a promising candidate for preventing radiation
Externí odkaz:
https://doaj.org/article/5c0c1cee3d764917825166a721740020
Autor:
Walid Shalata, Jeremy Zolnoorian, Amichay Meirovitz, Kim Sheva, Ashraf Abu Jama, Omar Abu Saleh, Alexander Yakobson
Publikováno v:
Life, Vol 13, Iss 1, p 40 (2022)
Dermatomyositis is a rare inflammatory myopathy that is often related to lung cancer. In this retrospective observational study, we analyzed data from patients diagnosed with lung cancer at Soroka University Medical Center between January 2017 and Ju
Externí odkaz:
https://doaj.org/article/20459d2094134273aee8c927d5b83587
Autor:
AVITAL GRANIT MIZRAHI, HANEEN HAMAD, AHINOAM GUGENHEIM, BENJAMIN NISMAN, ANNA KUZNETZ, INNA BEN DAVID, YAEL GELFEND, SHERRI COHEN, AVIAD ZICK, KIM SHEVA, HOVAV NECHUSHTAN, TAMAR PERETZ, AMICHAY MEIROVITZ
Publikováno v:
Anticancer Research. 42:5257-5263
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f18d2acb43051ae29914d38854ec7e3
https://doi.org/10.21873/anticanres.16032
https://doi.org/10.21873/anticanres.16032
Autor:
Walid Shalata, Sarah Weissmann, Sapir Itzhaki Gabay, Kim Sheva, Omar Abu Saleh, Ashraf Abu Jama, Alexander Yakobson, Keren Rouvinov
Publikováno v:
Cancers; Volume 14; Issue 21; Pages: 5451
Immune checkpoint inhibitors are a class of cancer treatment drugs that stimulate the immune system’s ability to fight tumor cells. These drugs are monoclonal antibodies targeting im-mune-inhibiting proteins on cancer cells, such as CTLA-4 and PD-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4323c85d2419b64d30a2550c5edb1618
https://pubmed.ncbi.nlm.nih.gov/36358869
https://pubmed.ncbi.nlm.nih.gov/36358869
Autor:
Nir Hirshoren, Cesar A. Perez, Sharon Daniel, Jeffrey M Weinberger, Shani Bergerson, Amichay Meirovitz, Kim Sheva, Evgeniya Bersudski
Publikováno v:
Cancer Reports. 5
Background The standard chemotherapy treatment protocol for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) requires as long as 56 days of hospitalization over six months. Where the 5-Fluorouracil (5-FU) pump is avail
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54edfc8557f17f6a2e728978510c0348
https://doi.org/10.1002/cnr2.1479
https://doi.org/10.1002/cnr2.1479
Autor:
Heba Alkhatib, Solomon Oguche, Efrat Flashner-Abramson, Kim Sheva, Amichay Meirovitz, Z. Granot, Swetha Vasudevan, Shira Stefansky, Nataly Kravchenko-Balasha, Tamar Peretz-Yablonsky, Avital Granit, Ittai Ben-Porath, Ariel Rubinstein
SummaryTriple negative breast cancer (TNBC) is an aggressive type of cancer that is known to be resistant to radiotherapy (RT). Evidence is accumulating that is indicative of the plasticity of TNBC, where one cancer subtype switches to another in res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc219cdd23c4c10be2c8759ccdf7e25a
https://doi.org/10.1101/2021.01.07.425553
https://doi.org/10.1101/2021.01.07.425553
